Literature DB >> 19935430

Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia.

Manuel Steiner1, Andishe Attarbaschi, Michael Dworzak, Herbert Strobl, Winfried Pickl, Rosa Kornmüller, Oskar Haas, Helmut Gadner, Georg Mann.   

Abstract

SUMMARY: Cytochemical myeloperoxidase (MPO) positivity represents the gold standard for discrimination between lymphatic and myeloid blasts. Rarely, cytochemical MPO reaction may be positive in >or=3% of blasts with clear lymphoblastic morphology. We present 5 patients with cytochemically MPO-positive acute leukemia classified as lymphoblastic by cytomorphology and lymphoblastic (n=3) or biphenotypic (n=2) by immunophenotyping, who entered first-line treatment for lymphoblastic leukemia. The former 3 are in first remission and both with biphenotypic leukemia relapsed with acute myeloid leukemia. The study primarily shows that cytochemical MPO expression in childhood acute leukemia revealing typical lymphoblastic morphology and phenotype does rarely exist. Although a small number of patients studied, cytochemical MPO expression in acute leukemia does not seem to require myeloid leukemia treatment in case of otherwise lymphoblastic cytomorphology and phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19935430     DOI: 10.1097/MPH.0b013e3181b1ee65

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  1 in total

1.  Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.

Authors:  L Lhermitte; E Mejstrikova; A J van der Sluijs-Gelling; G E Grigore; L Sedek; A E Bras; G Gaipa; E Sobral da Costa; M Novakova; E Sonneveld; C Buracchi; T de Sá Bacelar; J G Te Marvelde; A Trinquand; V Asnafi; T Szczepanski; S Matarraz; A Lopez; B Vidriales; J Bulsa; O Hrusak; T Kalina; Q Lecrevisse; M Martin Ayuso; M Brüggemann; J Verde; P Fernandez; L Burgos; B Paiva; C E Pedreira; J J M van Dongen; A Orfao; V H J van der Velden
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.